Stocktoria
TG THERAPEUTICS, INC. TGTX
TG THERAPEUTICS, INC. (TGTX) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $616.3M at a 72.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-27 | HC Wainwright & Co. | Buy (reit) |
| 2026-05-06 | HC Wainwright & Co. | Buy (main) |
| 2026-02-02 | JP Morgan | Overweight (main) |
| 2026-01-15 | Goldman Sachs | Neutral (main) |
| 2025-11-03 | JP Morgan | Overweight (main) |
| 2025-09-17 | B. Riley Securities | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.449 |
| Retained earnings / assets | -1.018 |
| EBIT / assets | 0.116 |
| Equity / liabilities | 1.561 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TGTX | TG THERAPEUTICS, INC. | 4/9 | 2.04 | 19.1 | +87.3% |
| OPK | OPKO HEALTH, INC. | 4/9 | -0.79 | — | -14.9% |
| INSM | INSMED Inc | 3/9 | -7.47 | — | +66.7% |
| AXSM | Axsome Therapeutics, Inc. | 4/9 | -5.64 | — | +65.5% |
| CPRX | CATALYST PHARMACEUTICALS, INC. | 4/9 | 14.1 | 18 | +19.8% |
| ORGO | Organogenesis Holdings Inc. | 3/9 | 5.27 | 8.4 | +17% |
| RARE | Ultragenyx Pharmaceutical Inc. | 4/9 | -9.61 | — | +20.2% |
About TG THERAPEUTICS, INC.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
FAQ
Is TGTX financially healthy?
TG THERAPEUTICS, INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does TGTX pay a dividend?
No, TG THERAPEUTICS, INC. does not currently pay a dividend.
How profitable is TGTX?
In FY2025, TG THERAPEUTICS, INC. had a net margin of 72.6% and a return on equity of 69.0%.
What is TGTX's P/E ratio?
TG THERAPEUTICS, INC.'s trailing price-to-earnings (P/E) ratio is about 19.1×, based on its latest annual earnings.
What is the analyst price target for TGTX?
The average Wall-Street price target for TG THERAPEUTICS, INC. is $51.71, about 4.5% above the recent price, from 7 analysts (consensus: buy).
Is TGTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on TG THERAPEUTICS, INC.: a Piotroski F-score of 4/9, an Altman Z″ in the grey zone, a P/E of about 19.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.